Ernexa Therapeutics (ERNAW) EBIT (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of EBIT data on file, last reported at -$5.6 million in Q1 2026.

• Quarterly EBIT fell 104.76% year-over-year to -$5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.2 million (up 3.48% YoY) and the FY2025 annual result came in at -$9.3 million, up 40.54% from the prior year.
• EBIT eased to -$5.6 million in Q1 2026, from -$2.1 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$2.0 million in Q3 2025 to a low of -$13.9 million in Q2 2022.
• A 5-year average of -$5.0 million and a median of -$4.9 million in 2024 frame the typical range for EBIT.
• Annual changes were most pronounced in 2022 — EBIT surged 90.38% — and 2026, when it slumped 104.76%.
• Tracing ERNAW's EBIT over 5 years: stood at -$4.7 million in 2022, then retreated by 21.7% to -$5.8 million in 2023, then jumped by 53.22% to -$2.7 million in 2024, then grew by 22.36% to -$2.1 million in 2025, then sank by 166.95% to -$5.6 million in 2026.
• The last three EBIT figures came in at -$5.6 million (Q1 2026), -$2.1 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.